Conference abstract · 11 Jan 2023
Review articlePublished 23 Aug 2021
Ivermectin in Covid-19: Important and Timely Updates for Family Medicine Physicians
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Ivermectin is not approved by the United States (US) Food and Drug Administration (FDA) for the treatment or prevention of COVID-19. Nonetheless, ivermectin prescriptions increased 11-fold from 3589 per week pre-COVID-19 to 39,102 by early 2021. In recent polls, 85% of the public trust their family medicine physicians as a source of reliable information on COVID-19 vaccinations. Ivermectin is FDA approved to treat intestinal strongyloidiasis and onchocerciasis orally, as well as ectoparasites and skin conditions topically. Possible side effects include skin rash, nausea, vomiting, diarrhea, stomach pain, facial or limb swelling, dizziness, seizures, confusion, hypotension, and liver injury. The United States (US) National Institutes of Health, World Health Organization, US FDA and European Medicines Agency have all advised against ivermectin for treatment or prevention of COVID-19 outside randomized trials. To do more good than harm in COVID-19 requires concerted efforts by competent and compassionate family medicine physicians who are deservedly the most trusted by the US public. In the US today, widespread vaccinations, masking, social distancing, crowd avoidance and frequent hand and face washing are remarkably effective and safe options. For ivermectin in COVID-19, family medicine physicians should reassure all patients that if a sufficient totality of evidence emerges, then this drug can be considered a therapeutic innovation and regulatory authorities will approve the drug. Thus, we strongly recommend that family physicians exert all reasonable efforts to increase vaccinations and have a moratorium on the prescription of ivermectin for COVID-19.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in General Medicine: Open Access.
Conference abstract · 11 Jan 2023
Massive pericardial effusion in a 9-year-old female with covid-19 associated multisystem inflammatory syndrome in children (mis-c): A case report
Conference abstract · 11 Jan 2023
Study of the prognostic factors of the relapse of laryngeal cancer after postoperative radiotherapy at the Cancer Center Emir Abdelkader of Oran Algeria
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalGeneral Medicine: Open Access
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Andreea Molnar”
- BylineArticles whose byline prints “Stephanie Lau”
- BylineArticles whose byline prints “Maja Berges”
- BylineArticles whose byline prints “Raymond B Masa”
- BylineArticles whose byline prints “Joshua J. Solano”
- BylineArticles whose byline prints “Scott M Alter”
- BylineArticles whose byline prints “Lisa M Clayton”
- BylineArticles whose byline prints “Richard D Shih”